Moderna (MRNA) Common Equity (2016 - 2026)

Moderna (MRNA) has 11 years of Common Equity data on file, last reported at $7.4 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $7.4 billion, down 26.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 billion (down 26.41% YoY), and the FY2025 annual result was $8.6 billion, down 20.65% from the prior year.
• Common Equity declined to $7.4 billion in Q1 2026 per MRNA's latest filing, from $8.6 billion in the prior quarter.
• Over five years, Common Equity peaked at $19.1 billion in Q4 2022 and troughed at $7.4 billion in Q1 2026.
• A 5-year average of $13.4 billion and a median of $12.8 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity jumped 344.89% in 2022, then slumped 32.05% in 2024.
• A 5-year view of Common Equity shows it stood at $19.1 billion in 2022, then slipped by 27.55% to $13.9 billion in 2023, then decreased by 21.32% to $10.9 billion in 2024, then dropped by 20.65% to $8.6 billion in 2025, then decreased by 14.36% to $7.4 billion in 2026.
• Business Quant data shows MRNA's Common Equity at $7.4 billion in Q1 2026, $8.6 billion in Q4 2025, and $9.3 billion in Q3 2025.